Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen s Q2 Revenues Almost Triple, Loss Narrows

NEW YORK, Aug. 3 (GenomeWeb News) - Nanogen yesterday reported a jump in revenues and narrowed losses for the second quarter of 2005.


The company's revenues for the quarter almost tripled, to $3.1 million from $1.1 million during the same period last year. Product revenues were $1.1 million of the total, up from $500,000 during the year-ago period. "We have built a good foundation on which new products and further acquisitions can be added. We are eagerly anticipating the shipment of new products later this fiscal year that will help us grow our revenue base and set the stage for significant growth during 2006," said CEO Howard Birndorf in a statement.


Research and development costs increased to $5.2 million from $4 million during last year's second quarter.


The company reported a net loss of $9.7 million, or $.20 per share, for the quarter, down from $12.9 million, or $.39 per share, for the same period in 2004.


As of June 30, Nanogen had $18.8 million in cash and cash equivalents and $13.1 million in short-term investments.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.